Libtayo is also under review by the EMA as a treatment for treatment-naïve NSCLC patients with PD-L1 expression of at least 50%, with a decision expected in the second quarter of 2021 ...
The European Medicines Agency’s CHMP scientific committee recommended that Sanofi and Regeneron’s Libtayo ... The conditional decision was based on the mid-stage EMPOWER-CSCC-1 trial and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback